Anaerobic bacteria and antibiotics: What kind of unexpected resistance could I find in my laboratory tomorrow?

Anaerobe

Volumn 16, Issue 6, 2010, Pages 555-559

  Dubreuil, L ^a   Odou, M F ^a  

^a Fac Sci Pharmaceut et Biologiques   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFALOTIN; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; DALBAVANCIN; DAPTOMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; METRONIDAZOLE; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; RAMOPLANIN; TEICOPLANIN; TICARCILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTEROIDES FRAGILIS; CLOSTRIDIUM; DRUG TREATMENT FAILURE; GRAM NEGATIVE SEPSIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PELVIS ABSCESS; PREVOTELLA LOESCHEII; PRIORITY JOURNAL; REVIEW; SUBDURAL EMPYEMA;

BACTEROIDES FRAGILIS; CLOSTRIDIA; CLOSTRIDIUM;

EID: 78650567162     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2010.10.002     Document Type: Review

References (66)

1. Dubreuil L. Méthodes d'étude des anaérobies. L'antibiogramme 2006, Eska, Paris. 2nd ed. P. Courvalin, R. Leclercq, E. Bingen (Eds.).
2. Koperna T., Schulz F. Prognosis and treatment of peritonitis. Do we need new scoring systems?. Arch Surg 1996, 131:180-186.
3. Salonen J.H., Eerola E., Meurman O. Clinical significance and outcome of anaerobic bacteremia. Clin Infect Dis 1998, 26:1413-1417.
4. King A., Downes J., Nord C.E., Phillips I., European Study Group Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic Gram-negative bacilli in Europe. Clin Microbiol Infect 1999, 5:404-416.
5. Koeth L.M., Good C.E., Appelbaum P.C., Goldstein E.J., Rodloff A.C., Claros M. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 2004, 53:1039-1044.
6. Valle G., Quiros L.M., Andres M.T., Fierro J.F. A β-lactamase belonging to group 2e from oral clinical isolates of Prevotella intermedia. FEMS Microbiol Lett 1998, 158:191-194.
7. Dubreuil L., Behra-Miellet J., Vouillot C., Bland S., Sedallian A., Mory F. β-lactamase production in Prevotella and in vitro susceptibilities to selected beta-lactam antibiotics. Int J Antimicrob Agents 2003, 21:267-273.
8. Turner K., Linquist L., Nord C.E. Purification and properties of a novel beta-lactamase from Fusobacterium nucleatum. Antimicrob Agents Chemother 1985, 27:943-947.
9. Nord C.E., Lindqvist L. A new betalactamase from Fusobacterium mortiferum. J Bacteriol 1992, 186:3415-3422. Program Abstr. 32th Intersci Conf Antimicrob Agents Chemother, Abstr. 1274.
10. Hart C.A., Makin T., Barr K., Cooke R.W.I. Characteristics of a β-lactamase produced by Clostridium butyricum. J Antimicrob Chemother 1982, 10:31-35.
11. Appelbaum P.C., Spangler S.K., Pankuch G.A., Philippon A., Jacobs M.R., Shiman R. Characterization of a β-lactamase from Clostridium clostridioforme. J Antimicrob Chemother 1994, 33:33-40.
12. Rogers M.B., Parker A.C., Smith C.J. Cloning and characterization of the endogenous cephalosporinase gene, cepA, from Bacteroides fragilis reveals a new subgroup of ambler class A β-lactamases. Antimicrob Agents Chemother 1993, 37:2391-2400.
13. Rogers M.C., Benett T.K., Payne C.M. Insertional activation of cep A leads to high level β lactamase expression in Bacteroides fragilis clinical isolates. J Bacteriol 1994, 176:4376-4384.
14. Dubreuil L. Anaérobies à Gram négatif. L'antibiogramme 2006, Eska, Paris. 2nd ed. P. Courvalin, R. Leclercq, E. Bingen (Eds.).
15. Wexler H., Getty C., Fisher G. Isolation and characterisation of a major outer membrane protein from B. distasonis. J Med Microbiol 1992, 37:165-175.
16. Wexler H.N., Read E.K., Tomzynski T.J. Characterization of omp200, a porin gene complex from Bacteroides fragilis: omp121 and omp71, gene sequence, deduced amino acid sequences and predictions of porin structure. Gene 2002, 283:95-105.
17. Odou M.F., Singer E., Romond M.B., Dubreuil L. Isolation and characterization of a porin-like protein of 45 kilodaltons from Bacteroides fragilis. FEMS Microbiol Lett 1998, 166:3347-3354.
18. Behra-Miellet J., Calvet L., Dubreuil L. A Bacteroides thetaiotamicron porin that could take part in resistance to beta-lactams. Int J Antimicrob Agents 2004, 24:135-143.
19. Dublanchet A., Caillon J., Edmond J.P., Chardon H., Drugeon H.B. Isolation of Bacteroides strains with reduced sensitivity to 5-nitroimidazoles. Eur J Clin Microbiol 1986, 5:346-347.
20. Trinh S., Reysset G. Detection by PCR of the nim genes encoding 5-nitroimidazole resistance in Bacteroides spp. J Clin Microbiol 1996, 34:2078-2084.
21. Fang H., Edlund C., Hedberg M., Nord C.E. New findings in beta-lactam and metronidazole resistant Bacteroides fragilis group. Int J Antimicrob Agents 2002, 19:361-370.
22. Lubbe M.M., Stanley K., Chakley L.J. Prevalence of nim genes in anaerobic/facultative anaerobic bacteria isolated in South Africa. FEMS Microbiol Lett 1999, 172:79-83.
23. Reysset G., Haggoud A., Sebald M. Genetics of resistance of Bacteroides species to 5-nitroimidazole. Clin Infect Dis 1993, 16(Suppl. 4). S401-S403.9, 63-65.
24. Trinh S., Haggoud A., Reysset G., Sebald M. Plasmids pIP 419 and pIP 421 from Bacteroides: 5-nitroimidazole resistance genes and their upstream insertion sequence elements. Microbiology 1995, 141:927-935.
25. Brazier J.S., Stubbs S.L., Duerden B.I. Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned?. J Antimicrob Chemother 1999, 44:580-581.
26. Gal M., Brazier J.S. Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants. J Antimicrob Chemother 2004, 54:109-116.
27. Schaumann R., Petzold S., Fille M., Rodloff A.C. Inducible metronidazole resistance in nim-positive and nim-negative Bacteroides fragilis group strains after several passages on metronidazole containing columbia agar plates. Infection 2005, 33:368-372.
28. Steffens L.S., Nicholson S., Paul L.V., Nord C.E., Patrick S., Abratt V.B. Bacteroides fragilis RecA protein overexpression causes resistance to metronidazole. Res Microbiol 2010, 161:346-354.
29. Lofmark S., Fang H., Hedberg M., Edlund C. Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob Agents Chemother 2005, 49:1253-1256.
30. Huang H., Weintaub A., Fang H., Nord C.E. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009, 34:516-522.
31. Vieira B.D., Boente R.F., Rodrigues Miranda K., Avelar K.E., Domingues R., Fereira M. Decreased susceptibility to nitroimidazoles among Bacteroides species in Brazil. Curr Microbiol 2006, 52:27-32.
32. Chauldhry R., Mathur P., Dhawan B., Kumar L. Emergence of metronidazole-resistant Bacteroides fragilis. India Emerging Infect Dis 2001, 7:485-486.
33. Schapiro J.M., Gupta R., Stefansson E., Fang F.C., Limaye A.P. Isolation of metronidazole-resistant Bacteroides fragilis carrying the nimA nitroreductase gene from a patient in Washington State. J Clin Microbiol 2004, 42:4127-4129.
34. Nagy E., Soli J., Urban E., Szoke I., Fodor E., Edwards R. Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary. Acta Biol Hung 2001, 52:271-280.
35. Wojcik-Stojek B., Bulanda M., Martirosian G., Heczko P., Meisel-Mikolajczyk F. In vitro antibiotic susceptibility of Bacteroides fragilis strains isolated from excised appendix of patients with phlegmonous or gangrenous appendicitis. Acta Microbiol Pol 2000, 49:171-175.
36. Marchandin H., JumasBilak E., Teyssier C., Jean-Pierre H., Mory F., Simeon de Buochberg M. Detection of nim genes in clinical isolates of Veillonella and Bacteroides fragilis in France. Anaerobe 2002, 8:137.
37. Marchandin H., Jean-Pierre H., Campos J., Dubreuil L., Teyssier C., Jumas-Bilak E. nimE gene in a metronidazole-susceptible Veillonella sp. strain. Antimicrob Agents Chemother 2004, 48:3207-3208.
38. Theron M.M., Van Rensburg M.N., Chalkley L.J. Nitroimidazole resistance genes (nimB) in anaerobic Gram-positive cocci (previously Peptostreptococcus spp.). J Antimicrob Chemother 2004, 54:240-242.
39. Faris B., Faris C., Clark J., Brown R., Poxton I.R. Metronidazole-resistant strain of Clostridium perfringens isolated from a clinical specimen. J Infect 1999, 39:164-165.
40. Brazier J.S., Fawley W., Freeman J., Wilcox M.H. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001, 48:741-742.
41. Wong S.S., Woo P.C., Luk W.K., Yuen K.Y. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E-test. Diagn Microbiol Infect Dis 1999, 34:1-6.
42. Jang S.S., Hansen L.M., Breher J.E., Riley D.A., Magdesian K.G., Madigan J.E. Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clin Infect Dis 1997, 25(Suppl. 2):S266-267.
43. Pelaez T., Alcala L., Alonso R., Rodriguez-Creixems M., Garcia-Lechuz J.M., Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002, 46:1647-1650.
44. Elsaghier A.A., Brazier J.S., James E.A. Bacteraemia due to Bacteroides fragilis with reduced susceptibility to metronidazole. J Antimicrob Chemother 2003, 51:1436-1437.
45. Sandoe J.A.T., Struthers J.K., Brazier J.S. Subdural empyema caused by Prevotella loescheii with reduced susceptibilty to metronidazole. J Antimicrob Chemother 2001, 47:366-367.
46. Rotimi V.O., Khoursheed M., Brazier J.S., Jamal W.Y., Khodakhast F.B. Bacteroides species highly resistant to metronidazole: an emerging clinical problem. Clin Microbiol Infect 1999, 5:166-169.
47. Mory F., Carlier J.P., Alauzet C., Schuchmacher M., Losniewski A. Bacteremia caused by a metronidazole-resistant Prevotella sp. strain. Clin Inf Dis 2005, 43:5380-5383.
48. Citron D.M., Merriam C.V., Tyrell K.L., Warren Y.A., Fernandez H., Goldstein E.J.C. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003, 47:2334-2338.
49. Mory F., Lozniewski A., David V., Carlier J.P., Dubreuil L., Leclercq R. Low-level vancomycin resistance in Clostridium innocuum. J Clin Microbiol 1998, 36:1767-1768.
50. Mory F., Loczniewski A., Bland S., Sedallian A., Grollier G., Girard-Pipau F., Paris M.F., Dubreuil L. Survey of anaerobic susceptibility patterns: a French multicentric study. Int J Antimicrob Agents 1998, 10:229-236.
51. David V., Bozdogan B., Mainardi J.L., Legrand R., Gutmann L., Leclercq R. Mechanism of intrinsic resistance to vancomycin in Clostridium innocuum NCIB 10674. J Bacteriol 2004, 186:3415-3422.
52. Stinear T.P., Olden D.C., Jonhson P.D., Davies J.K., Grayson M.L. Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet 2001, 17:855-856.
53. Ballard S.A., Grabsch E.A., Johnson P.D., Grayson M.L. Comparison of three PCR primer sets for identification of vanB gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by vanB-containing anaerobic bacilli. Antimicrob Agents Chemother 2005, 49:77-81.
54. Ballard S.A., Pertile K.K., Lim M., Johnson P.D., Grayson M.L. Molecular Characterization of vanB elements in naturally occurring gut anaerobes. Antimicrob Agents Chemother 2005, 49:1688-1694.
55. Domingo M.C., Huletsky A., Bernal A., Giroux R., Boudreau D.K., Picard F.J. Characterization of a Tn5382-like transposon containing the vanB2 gene cluster in a Clostridium strain isolated from human faeces. Antimicrob Chemother 2005, 55:466-474.
56. Launay A., Ballard S.A., Johnson P.D., Grayson M.L., Lambert T. Transfer of vancomycin resistance transposon Tn1549 from Clostridium symbiosum to Enterococcus spp. in the gut of a gnotobiotic mice. Antimicrob Agents Chemother 2006, 50:1054-1062.
57. Dubreuil L., Breuil J., Dublanchet A. Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992. Eur J Clin Microbiol Infect Dis 1992, 11:1094-1099.
58. Grollier G., Mory F., Quentin C., Girard-Pipau F., Tigaud S., Sedallian A. Survey of anaerobic susceptibility patterns: a French multicentric study. Path Biol 1994, 42:498-504.
59. Bland S., Sédallian A., Grollier G., Mory F., Houcke I., Dubreuil L. In vitro activity of three carbapenems biapenem, imipenem and meropenem and some other antibiotics against anaerobic bacteria. Path Biol 1995, 43:289-293.
60. Dubreuil L. Bacteroides fragilis: état de la sensibilité aux antibiotiques, évolution des résistances. Médecine et maladies infectieuses 1996, 26:196-207.
61. Dubreuil L., Singer E., Jaulhac B., Mory F., Lozniewski A., Bland S. Sensibilité des anaérobies stricts aux antibiotiques. Antibiotiques 1999, 1:147-153.
62. Behra-Miellet J., Dubreuil L., Jumas-Bilak E. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int J Antimicrob Agents 2002, 20:366-374.
63. Behra-Miellet J., Calvet L., Mory F., Muller C., Chomarat M., Bézian M.C. Antibiotic resistance among anaerobic Gram negative bacilli: lessons from a French multicentric survey. Anaerobe 2003, 9:105-111.
64. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y.A., Tyrrel K.L., Fernandez H.T. In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and Corynebacteria. Antimicrob Agents Chemother 2003, 47:1968-1971.
65. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y.A., Tyrrel K.L., Fernandez H.T. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 2004, 48:2149-2152.
66. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., Fernandez H.T. Comparative in vitro activities of XRP-2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin and ampicillin against anaerobic Gram-positive species, actinomycetes and lactobacilli. Antimicrob Agents Chemother 2005, 49:408-413.